Cartalax Peptide Research Guide 2026: Khavinson Bioregulator for Cartilage

# Cartalax Peptide Research Guide 2026: Khavinson Bioregulator for Cartilage

For Research Use Only. Not for human use. Not for clinical or veterinary diagnostic use.

Introduction

Cartalax is a naturally derived peptide bioregulator developed by the Khavinson Institute (St. Petersburg, Russia) with a specific focus on cartilage tissue regeneration and joint health. The compound represents a class of tissue-specific bioregulators — short peptide sequences derived from animal tissue extracts — that are hypothesized to restore tissue-specific gene expression patterns through epigenetic modulation.

Khavinson bioregulators operate on the principle that aging and tissue dysfunction are associated with dysregulation of tissue-specific gene expression, and that short peptides derived from target tissue can restore normal expression patterns by acting as signaling molecules. Cartalax specifically targets chondrocytes (cartilage-forming cells) and cartilage matrix maintenance.

Structure & Composition

Amino Acid Sequence

Cartalax is an oligopeptide composed of:

• •Alanine (Ala)
• •Glutamic acid (Glu)
• •Aspartic acid (Asp)
• •Leucine (Leu)

The specific sequence Ala-Glu-Asp-Leu is the active component, typically conjugated with small molecular cofactors in some formulations. Molecular weight approximately 420–450 Da depending on conjugation state.

Bioregulator Class

Cartalax belongs to the Khavinson bioregulator family, which includes:

Mechanism of Action

Epigenetic Modulation Hypothesis

Bioregulators are proposed to function via:

1. Tissue-specific uptake — Short peptides penetrate tissue barriers and are preferentially taken up by target cells via cell surface receptors

2. Transcription factor modulation — Interaction with transcription factors or signaling pathways that regulate tissue-specific genes

3. Gene expression restoration — Upregulation of genes involved in cartilage matrix synthesis (collagen II, aggrecan, COMP)

4. Downregulation of catabolic factors — Reduced expression of matrix metalloproteinases (MMPs) and inflammatory mediators (TNF-α, IL-1β)

Chondrocyte-Specific Effects (Proposed)

• •Increased collagen type II synthesis — Primary structural collagen in cartilage
• •Enhanced proteoglycan production — Aggrecan and other cartilage matrix proteoglycans
• •Reduced matrix breakdown — Decreased MMP activity and cartilage degradation
• •Anti-inflammatory signaling — Modulation of NF-κB and other pro-inflammatory pathways

Research Applications

Osteoarthritis & Joint Health

Cartalax has been investigated in research models of:

• •Cartilage degeneration — Age-related and injury-induced chondrocyte dysfunction
• •Osteoarthritis progression — Slowing of cartilage loss and joint space narrowing
• •Post-injury recovery — Support of chondrocyte proliferation after acute cartilage trauma
• •Chronic joint inflammation — Reduction of synovitis and inflammatory mediators

Aging & Connective Tissue

Broader research interest in:

• •Aging-associated cartilage changes — Restoration of youthful chondrocyte gene expression
• •Collagen cross-linking — Matrix integrity and mechanical properties
• •Tissue elasticity — Preservation of cartilage resilience with age

Administration & Protocols

Formulation

Cartalax is available in multiple delivery formats:

1. Sublingual bioregulator tablets — Enteric-coated peptides, mucosa absorption

2. Oral capsules — Gastrointestinal delivery (lower bioavailability)

3. Subcutaneous injection (research) — Direct tissue delivery in controlled studies

4. Topical formulations — Transdermal or local delivery to joint tissue

Sublingual Administration (Standard)

Typical protocol:

• •Dose: 1–2 tablets (5–10 mg peptide), sublingual dissolution
• •Frequency: 1–2× daily, often 30 minutes before food
• •Duration: 10–14 day cycles, repeated monthly or as directed
• •Storage: Room temperature, protected from moisture

Subcutaneous Injection (Research Settings)

For controlled research:

• •Diluent: Bacteriostatic water or sterile saline
• •Concentration: Typically 1–2 mg/mL
• •Dose: 1–3 mg per injection
• •Frequency: Daily or every other day, 10–14 day cycles
• •Route: Subcutaneous (abdomen, thigh)

Cycle Protocols

Bioregulators are typically administered in cycles:

Standard cycle:

• •Administration period: 10–14 consecutive days
• •Rest period: 2–4 weeks
• •Repetition: Cycle repeated 3–4 times annually

This pulsatile approach is hypothesized to maintain cellular responsiveness and allow epigenetic "reset" between cycles.

Quality & Sourcing Considerations

Verification Parameters

When sourcing Cartalax:

1. Purity certification — HPLC confirmation of Ala-Glu-Asp-Leu peptide

2. Molecular weight — 420–450 Da by mass spectrometry

3. Khavinson certification — Authentic Khavinson Institute formulations carry documentation

4. Microbiological testing — Sterility and bacterial/fungal culture negativity

5. Storage conditions — Dry, cool, protected from light

Supplier Notes

Authentic Khavinson bioregulators are produced in Russia and imported through authorized distributors. Verify supplier credentials and certificates of analysis. Cross-reference availability on the Peptides.SO platform.

Regulatory Status & Availability

Russia & Eastern Europe

• •Regulatory status: Approved as dietary supplements and therapeutic agents
• •Khavinson Institute: Licensed manufacturer and primary developer
• •Prescriptive use: Often recommended by Russian/Eastern European practitioners

United States & Western Markets

• •FDA status: Not FDA-approved; classified as dietary supplement or research peptide
• •Distribution: Available through specialized suppliers; not in mainstream pharmacies
• •Legal status: Permitted for research and personal use in most jurisdictions

Clinical Research

As of 2026, Cartalax has limited published Western clinical trials. Most research literature comes from Russian and Eastern European sources; Western scientific validation remains incomplete.

RUO Status & Disclaimers

Cartalax is an investigational bioregulator intended for research use only:

• •Clinical efficacy: Not established in rigorous Western trials; preliminary data from Russian clinical settings
• •Not for self-administration: Outside approved therapeutic frameworks
• •Regulatory uncertainty: Status varies by jurisdiction
• •Research framework: Subject to institutional review and compliance with research protocols

Comparison with Related Bioregulators & Joint-Support Compounds

Conclusion

Cartalax represents the Khavinson Institute's targeted approach to cartilage tissue regeneration through peptide bioregulation. The Ala-Glu-Asp-Leu oligopeptide is hypothesized to restore tissue-specific gene expression and support chondrocyte function through epigenetic mechanisms. While research interest is significant in Russia and Eastern Europe, Western clinical validation remains limited. For researchers investigating cartilage regeneration, aging-associated joint dysfunction, or tissue-specific peptide signaling, Cartalax offers a unique bioregulator tool with a distinct mechanistic profile.

---

Related Guides:

• •/learn/epithalon-epitalon-complete-research-guide-2026-telomere-longevity
• •/learn/bpc-157-complete-research-guide
• •/calculator